Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2019

Open Access 01-12-2019 | Acupuncture | Study protocol

Hypoglossal acupuncture for acute chemotherapy-induced dysgeusia in patients with breast cancer: study protocol of a randomized, sham-controlled trial

Authors: Heidemarie Haller, Taige Wang, Romy Lauche, Kyung-Eun Choi, Petra Voiß, Sabine Felber, Holger Cramer, Beyhan Ataseven, Sherko Kümmel, Anna Paul, Gustav Dobos

Published in: Trials | Issue 1/2019

Login to get access

Abstract

Background

Distortion of taste sensations is a common chemotherapy-induced side effect; however, treatment evidence is limited. Pilot data indicated that acupuncture might be able to improve symptoms of dysgeusia. Thus, the aim of this study is to investigate the effects and side effects of hypoglossal acupuncture in the treatment of dysgeusia in patients with breast cancer undergoing chemotherapy.

Methods/design

The study is a randomized controlled trial comparing a single verum acupuncture treatment with two active comparators: sham acupuncture and dietary recommendations. Sample size calculation revealed a total of 75 patients pending an alpha of 0.05, a power of 0.8, and an estimated effect size of 0.80. Patients with breast cancer undergoing platinum- or taxane-based chemotherapy will be included if they present with phantogeusia (abnormal taste sensations without an external oral stimulus) with an intensity of 4 points or above on an 11-point numeric rating scale (NRS). The primary outcome is phantogeusia; secondary outcomes include parageusia (abnormal taste of food), hypogeusia (reduced taste sensations), hypergeusia (increased taste sensations), xerostomia (dry mouth), stomatitis, appetite, and functional impairment. All outcomes will be assessed at baseline and prior to the next chemotherapy administration using an 11-point NRS for each. All adverse events will be recorded.

Discussion

The results of this study will demonstrate the extent to which hypoglossal acupuncture may influence the intensity of and functional impairment due to chemotherapy-induced dysgeusia.

Trial registration

Clinical Trials.gov, NCT02304913. Registered on 19 November 2014.
Literature
1.
Chaveli-Lopez B. Oral toxicity produced by chemotherapy: a systematic review. J Clin Exp Dent. 2014;6(1):e81–90.CrossRef
2.
Mosel DD, Bauer RL, Lynch DP, Hwang ST. Oral complications in the treatment of cancer patients. Oral Dis. 2011;17(6):550–9.CrossRef
3.
Hovan AJ, Williams PM, Stevenson-Moore P, Wahlin YB, Ohrn KE, Elting LS, Spijkervet FK, Brennan MT. A systematic review of dysgeusia induced by cancer therapies. Support Care Cancer. 2010;18(8):1081–7.CrossRef
4.
Galizia D, Milani A, Geuna E, Martinello R, Cagnazzo C, Foresto M, Longo V, Berchialla P, Solinas G, Calori A, et al. Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: a prospective study. Cancer Med. 2018;7(9):4339–44.CrossRef
5.
Halyard MY. Taste and smell alterations in cancer patients - real problems with few solutions. J Support Oncol. 2009;7(2):68–9.PubMed
6.
Speck RM, DeMichele A, Farrar JT, Hennessy S, Mao JJ, Stineman MG, Barg FK. Taste alteration in breast cancer patients treated with taxane chemotherapy: experience, effect, and coping strategies. Support Care Cancer. 2013;21(2):549–55.CrossRef
7.
Hong JH, Omur-Ozbek P, Stanek BT, Dietrich AM, Duncan SE, Lee YW, Lesser G. Taste and odor abnormalities in cancer patients. J Support Oncol. 2009;7(2):58–65.PubMed
8.
Buntzel J, Schuth J, Kuttner K, Glatzel M. Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Support Care Cancer. 1998;6(2):155–60.CrossRef
9.
Komaki R, Lee JS, Milas L, Lee HK, Fossella FV, Herbst RS, Allen PK, Liao Z, Stevens CW, Lu C, et al. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys. 2004;58(5):1369–77.CrossRef
10.
Halyard MY, Jatoi A, Sloan JA, Bearden JD 3rd, Vora SA, Atherton PJ, Perez EA, Soori G, Zalduendo AC, Zhu A, et al. Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4). Int J Radiat Oncol Biol Phys. 2007;67(5):1318–22.CrossRef
11.
Strasser F, Demmer R, Bohme C, Schmitz SF, Thuerlimann B, Cerny T, Gillessen S. Prevention of docetaxel- or paclitaxel-associated taste alterations in cancer patients with oral glutamine: a randomized, placebo-controlled, double-blind study. Oncologist. 2008;13(3):337–46.CrossRef
12.
Wong HM. Oral complications and management strategies for patients undergoing cancer therapy. Sci World J. 2014;2014:581795.
13.
Brandt H, Hauswald B, Langer H, Gleditsch J, Zahnert T. Efficacy of acupuncture in the treatment of idiopathic taste disorders: a randomized placebo-controlled trial [in German]. German J Acupunct Relat Tech. 2008;51(1):24–31.
14.
Nagraj SK, Naresh S, Srinivas K, Renjith George P, Shrestha A, Levenson D, Ferraiolo DM. Interventions for the management of taste disturbances. Cochrane Database Syst Rev. 2014;11:CD010470.
15.
Chiu HY, Hsieh YJ, Tsai PS. Systematic review and meta-analysis of acupuncture to reduce cancer-related pain. Eur J Cancer Care. 2016;26:e12457.CrossRef
16.
Garcia MK, McQuade J, Haddad R, Patel S, Lee R, Yang P, Palmer JL, Cohen L. Systematic review of acupuncture in cancer care: a synthesis of the evidence. J Clin Oncol. 2013;31(7):952–60.CrossRef
17.
Wu X, Chung VC, Hui EP, Ziea ET, Ng BF, Ho RS, Tsoi KK, Wong SY, Wu JC. Effectiveness of acupuncture and related therapies for palliative care of cancer: overview of systematic reviews. Sci Rep. 2015;5:16776.CrossRef
18.
Li LX, Tian G, He J. The standardization of acupuncture treatment for radiation-induced xerostomia: a literature review. Chin J Integr Med. 2016;22(7):549–54.CrossRef
19.
Deadman P, Al-Khafaji M. Manual of acupuncture. Hove: Journal of Chinese Medicine Publications; 2007.
20.
Chan A, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200–7.CrossRef
21.
Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332.CrossRef
22.
MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D. Revised Standards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. J Evid Based Med. 2010;3(3):140–55.CrossRef
23.
Campagna S, Gonella S, Sperlinga R, Giuliano PL, Marchese R, Pedersini R, Berchialla P, Dimonte V. Prevalence, severity, and self-reported characteristics of taste alterations in patients receiving chemotherapy. Oncol Nurs Forum. 2018;45(3):342–53.CrossRef
24.
Ng K, Woo J, Kwan M, Sea M, Wang A, Lo R, Chan A, Henry CJ. Effect of age and disease on taste perception. J Pain Symptom Manag. 2004;28(1):28–34.CrossRef
25.
Saghaei M. Random allocation software for parallel group randomized trials. BMC Med Res Methodol. 2004;4:26.CrossRef
26.
Birch S. Controlling for non-specific effects of acupuncture in clinical trials. Clin Acup Orien Med. 2003;4(2–3):59–70.CrossRef
27.
Lu W, Wayne PM, Davis RB, Buring JE, Li H, Goguen LA, Rosenthal DS, Tishler RB, Posner MR, Haddad RI. Acupuncture for dysphagia after chemoradiation in head and neck cancer: rationale and design of a randomized, sham-controlled trial. Contemp Clin Trials. 2012;33(4):700–11.CrossRef
28.
Deutsche Krebshilfe. Die blauen Ratgeber - Ernährung bei Krebs. Bonn: Deutsche Krebshilfe; 2014.
29.
Lyckholm L, Heddinger SP, Parker G, Coyne PJ, Ramakrishnan V, Smith TJ, Henkin RI. A randomized, placebo controlled trial of oral zinc for chemotherapy-related taste and smell disorders. J Pain Palliat Care Pharmacother. 2012;26(2):111–4.CrossRef
30.
Steinbach S, Hummel T, Bohner C, Berktold S, Hundt W, Kriner M, Heinrich P, Sommer H, Hanusch C, Prechtl A, et al. Qualitative and quantitative assessment of taste and smell changes in patients undergoing chemotherapy for breast cancer or gynecologic malignancies. J Clin Oncol. 2009;27(11):1899–905.CrossRef
31.
European Medicines Agency. ICH harmonized tripartite guideline E6: note for guidance on good clinical practice (PMP/ICH/135/95). London: European Medicines Agency; 2002.
32.
Borkovec TD, Nau SD. Credibility of analogue therapy rationales. J Behav Ther Exp Psychiatry. 1972;3:257–60.CrossRef
33.
Vincent CA. Credibility assessment in trials of acupuncture. Compl Med Res. 1990;1:8–11.
34.
Bang H, Ni L, Davis CE. Assessment of blinding in clinical trials. Control Clin Trials. 2004;25(2):143–56.CrossRef
35.
Kolahi J, Bang H, Park J. Towards a proposal for assessment of blinding success in clinical trials: up-to-date review. Community Dent Oral Epidemiol. 2009;37(6):477–84.CrossRef
36.
Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175–91.CrossRef
37.
Rubin DB. Multiple imputation for nonresponse in surveys. New York: Wiley; 1987.CrossRef
38.
Schafer JL. Analysis of incomplete multivariate data. New York: Chapman and Hall; 1997.CrossRef
39.
Hamasaki T, Asakura K, Evans SR, Sugimoto T, Sozu T. Group-sequential strategies in clinical trials with multiple co-primary outcomes. Stat Biopharm Res. 2015;7(1):36–54.CrossRef
40.
Lund I, Naslund J, Lundeberg T. Minimal acupuncture is not a valid placebo control in randomised controlled trials of acupuncture: a physiologist's perspective. Chin Med. 2009;4:1.CrossRef
41.
Lundeberg T, Lund I, Sing A, Naslund J. Is placebo acupuncture what it is intended to be? Evid Based Complement Alternat Med. 2011;2011:932407.CrossRef
42.
White AR, Filshie J, Cummings TM, International Acupuncture Research Forum. Clinical trials of acupuncture: consensus recommendations for optimal treatment, sham controls and blinding. Complement Ther Med. 2001;9(4):237–45.CrossRef
Metadata
Title
Hypoglossal acupuncture for acute chemotherapy-induced dysgeusia in patients with breast cancer: study protocol of a randomized, sham-controlled trial
Authors
Heidemarie Haller
Taige Wang
Romy Lauche
Kyung-Eun Choi
Petra Voiß
Sabine Felber
Holger Cramer
Beyhan Ataseven
Sherko Kümmel
Anna Paul
Gustav Dobos
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Trials / Issue 1/2019
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-019-3525-y

Other articles of this Issue 1/2019

Trials 1/2019 Go to the issue

Study protocol

Comparison of 22G standard and Franseen needles in endoscopic ultrasound-guided fine-needle aspiration for diagnosing pancreatic mass lesions: Study protocol for a controlled trial

Research

Adverse effects of xenogenic scaffolding in the context of a randomized double-blind placebo-controlled study for repairing full-thickness rotator cuff tears

Study protocol

Virtual reality as an adjunct to anesthesia in the operating room

Study protocol

Achieving Self-Directed Integrated Cancer Aftercare (ASICA) in melanoma: protocol for a randomised patient-focused pilot trial of delivering the ASICA intervention as a means to earlier detection of recurrent and second primary melanoma

Study protocol

Effect of acupuncture on lung cancer-related fatigue: study protocol for a multi-center randomized controlled trial

Study protocol

Glibenclamide in aneurysmatic subarachnoid hemorrhage (GASH): study protocol for a randomized controlled trial